NEW YORK--(BUSINESS WIRE)-- OS Therapies Inc. (NYSE-A: OSTX), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, has announced its submission for a Regenerative Medicine Advanced Therapy (RMAT) Designation to the U.S. FDA for OST-HER2. This designation is sought for the prevention of metastases in recurrent, fully-resected, lung metastatic pediatric osteosarcoma. If granted, OST-HER2 would become the first listeria investigational medicinal product to receive the RMAT designation. This designation would facilitate an accelerated Biologics License Application $(BLA.AU)$ review and enhance interactions with the FDA to streamline market access. The company anticipates feedback from a Type D meeting with the FDA by mid-June 2025, which will inform their End of Phase 2 meeting request and potential rolling BLA submission in the third quarter of 2025.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。